Form 4: CERO CFO Kucharchuk Granted Over 1.1M Stock Options

CERO Therapeutics Holdings, Inc. Chief Financial Officer Andrew Kucharchuk was granted 1,162,099 stock options with an exercise price of $0.055.

Summary

• Andrew Albert Kucharchuk, Chief Financial Officer of CERO Therapeutics Holdings, Inc. (CERO), was granted 1,162,099 stock options.
• The transaction date for this grant was January 7, 2026.
• Each stock option has an exercise price of $0.055.
• The options become exercisable on January 7, 2026, and will expire on January 6, 2036.
• Following this transaction, Mr. Kucharchuk beneficially owns 1,162,099 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating alignment of interests and incentivizing long-term performance. It is not a direct indicator of immediate financial performance but reflects confidence in future potential.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing performance and value creation.
• The options have a 10-year expiration period, providing a significant window for potential value realization.

Negatives

• The filing does not present any immediate negative financial implications for the company, as it pertains to equity compensation rather than operational performance.

Future Outlook

The grant of long-term stock options to a key executive like the CFO suggests a strategic move to retain talent and motivate leadership towards achieving long-term company objectives and shareholder value growth.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for early-stage companies like CERO Therapeutics, to attract, retain, and incentivize key executives. This form of equity compensation is standard for aligning executive interests with the long-term success of the company.

Comparison to Industry Standards

• Executive equity compensation, particularly through stock option grants, is a widely adopted practice across the biotech sector, comparable to compensation structures seen in companies like Moderna or BioNTech during their growth phases, aiming to tie executive rewards directly to company performance and stock appreciation.
• The 10-year term for the options is a standard duration for executive incentive plans, providing a long-term horizon for value creation, similar to grants observed at other emerging life sciences companies.

Related Party Transactions

• The grant of stock options to Andrew Albert Kucharchuk, the Chief Financial Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer. This is a standard form of executive compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the CFO's financial interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees: Such compensation practices can signal a commitment to rewarding key personnel, potentially boosting morale and retention among the broader employee base.

Next Steps

• The Chief Financial Officer may choose to exercise these options at any point between the exercisable date (January 7, 2026) and the expiration date (January 6, 2036), provided the stock price is above the exercise price of $0.055.

Key Dates

Keywords

CERO Therapeutics Holdings, CERO, stock options, equity compensation, insider transaction, CFO, Form 4, beneficial ownership